(Q44507067)

3 December 2017

title

Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate (English)

1 reference

3 December 2017

main subject

coronary artery disease

1 reference

Douglas H Deutschman

1

1 reference

3 December 2017

Jeffrey S Carstens

2

1 reference

3 December 2017

Robert L Klepper

3

1 reference

3 December 2017

Wyatt S Smith

4

1 reference

3 December 2017

M Trevor Page

5

1 reference

3 December 2017

Thomas R Young

6

1 reference

3 December 2017

Lisa A Gleason

7

1 reference

3 December 2017

Nobuko Nakajima

8

1 reference

3 December 2017

Roger A Sabbadini

9

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

3 December 2017

published in

American Heart Journal

1 reference

3 December 2017

volume

146

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

62-68

1 reference

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Physiology and pathophysiology of sphingolipid metabolism and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Sphingolipid mediators in cardiovascular cell biology and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Lysophosphatidic acid and sphingosine 1-phosphate: two lipid villains provoking cardiovascular diseases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Tumor necrosis factor- induces adhesion molecule expression through the sphingosine kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Tumor necrosis factor-alpha, sphingosine, ceramide: which is the appropriate marker of inflammation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

von Willebrand factor: a marker of endothelial damage?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900118-2

10.1016/S0002-8703(03)00118-2

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference